Molecular Residual Disease (MRD) testing is a powerful tool for predicting the likelihood of cancer recurrence or progression, surpassing traditional methods, and informing treatment decisions through the analysis of circulating tumor DNA (ctDNA).
Rapid generation of the patient-specific signature
Actionable insights from a single blood sample (< 8 mL)
Ultra-sensitive and accurate
14 working days turn-around time
Circulating Tumor DNA Allows for Early Detection of Recurrence And Precise Measurement of Tumor Burden.
Our ultra-sensitive test detects molecular traces of ctDNA through comprehensive tracking of the entire tumor mutation signature including aggregating complex features such as CNV and SNV. Therefore, an ultra-low number of cells can be detected compared to standard-of-care imaging.
Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process.
All included test
After confirmation of the order, we dispatch the test kits, which include a solid biopsy block/slides holder and a barcoded blood collection tube, to the designated medical institution.
Whole genome sequencing
We filter out noise to derive a patient-specific cancer mutational signature. Using thousands of data points across the entire genome, we identify the genetic pattern of a patient's tumor.
AI & Advanced Signal Processing
MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring.
Clinical validation by scientific team
Our team of oncology experts reviews each report before making it available for the clinician
Enhanced efficiency, reduced overall costs, and achieve a clearer demonstration of the long-term durability of treatment responses.
Enable Pharma partners towards genomics-driven drug development, leading to quicker and more cost-effective drug development.
C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.
MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.
MRD test provides results in the form of a binary score (positive or negative).
Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection
Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer.
Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).
The turnaround time is 14 Days.
Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.